Abstract
Omalizumab is frequently used as add-on treatment to inhaled corticosteroids (ICS) and long-acting β2-agonists in patients with suboptimal control of severe asthma. Patients with severe asthma will typically require chronic treatment, although due to the limited amount of data available there are still some concerns about the safety and efficacy of long-term therapy with omalizumab. Herein, in an extension of a previous 4-year study, we report disease-related outcomes of 8 patients with severe persistent allergic asthma who have been followed for a total of 9 years in a real-life setting. Both quality of life (QoL) (evaluated using the Juniper Asthma-Related QoL Questionnaire [AQLQ]) and forced expiratory volume in 1 second (FEV1) showed sustained improvement at 9 years. The median values of AQLQ and FEV1 at 4 years were 5.5 and 82.0% compared to 5.9 and 85.5%, respectively, at 9 years, which were all significantly increased from baseline. After 9 years, the mean annual number of severe exacerbations was 0.63 compared to 5 at baseline. There also appeared to be a trend toward use of a lower dose of ICS at longer follow-up times. After 9 years, there were no safety concerns for continued use of omalizumab, and no asthma-related ...Continue Reading
References
Apr 1, 1993·The American Review of Respiratory Disease·E F JuniperL E Griffith
Apr 1, 1996·The European Respiratory Journal·P J BarnesJ B Klim
Jul 17, 2004·American Journal of Respiratory and Critical Care Medicine·Eric D BatemanUNKNOWN GOAL Investigators Group
Feb 1, 2005·Allergy·M HumbertK Surrey
Nov 6, 2007·The Journal of Allergy and Clinical Immunology·Lucia CazzolettiUNKNOWN Therapy and Health Economics Group of the European Community Respiratory Health Survey
Jan 2, 2008·The European Respiratory Journal·E D BatemanH J Zar
Aug 7, 2010·Chest·Gustavo J RodrigoJosé A Castro-Rodriguez
Mar 12, 2011·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Elisabetta PaceMark Gjomarkaj
Dec 14, 2011·Pulmonary Pharmacology & Therapeutics·Eleni G TzortzakiNikolaos M Siafakas
Feb 11, 2012·Therapeutic Advances in Respiratory Disease·Francesco MenzellaLuigi Zucchi
Jun 25, 2015·Allergy and Asthma Proceedings·James L ZazzaliMichael Schatz
Dec 9, 2015·Allergy·I AbrahamK MacDonald
Apr 30, 2016·Allergy, Asthma & Immunology Research·Jing LiUNKNOWN China Omalizumab Study Group
Nov 9, 2016·Allergy, Asthma & Immunology Research·Merritt L Fajt, Sally E Wenzel
Citations
May 8, 2018·Immunity, Inflammation and Disease·S Gunnar O JohanssonAnna Nopp
Oct 13, 2017·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·K SchröderU Pleyer
Feb 8, 2018·Medical Principles and Practice : International Journal of the Kuwait University, Health Science Centre·Mona Al-AhmadEdin Jusufovic
Nov 8, 2018·Therapeutic Advances in Respiratory Disease·Corrado PelaiaGirolamo Pelaia
Sep 17, 2019·American Journal of Respiratory and Critical Care Medicine·Eugene R BleeckerTrung N Tran
Oct 24, 2017·Current Opinion in Pulmonary Medicine·Marc HumbertNicola A Hanania
Nov 28, 2018·Allergy, Asthma & Immunology Research·Min Hye KimYou Sook Cho
May 1, 2019·Therapeutic Advances in Respiratory Disease·Giorgio Lorenzo ColomboFrancesco Menzella
Sep 29, 2020·Journal of Asthma and Allergy·Francesco MenzellaNicola Facciolongo
Feb 15, 2019·Expert Review of Clinical Immunology·Karen M MacDonaldIvo Abraham
Apr 21, 2018·Allergy, Asthma & Immunology Research·Sang Heon KimUNKNOWN Severe Asthma Work Group, the Korean Academy of Asthma, Allergy and Clinical Immunology
Jul 1, 2020·Terapevticheskiĭ arkhiv·O V SkorokhodkinaV A Pozdnyak
Dec 18, 2020·Frontiers in Immunology·Corrado PelaiaGirolamo Pelaia
Jan 25, 2021·The Journal of Allergy and Clinical Immunology. in Practice·Jean BousquetFrancis Nissen
Apr 4, 2021·Biomedicines·Francesco MenzellaNicola Cosimo Facciolongo
Jul 7, 2021·Respiratory Medicine·Min ZhangShengdao Xiong
Sep 17, 2021·The Journal of Allergy and Clinical Immunology·Philippe GevaertClaus Bachert